## Top 20 translational researchers of 2014

Brady Huggett \& Kathryn Paisner

Our ranking of biotech's top translational researchers (Table 1) is based on patent analytics firm IP Checkups examination of 2014's most active scientists for patenting. The table also includes each researcher's most-cited patent from the prior five years and their H index (calculated to measure the impact of a scientist's body of
published work; higher = more impact). Table 2 lists the most-cited patents overall from the 2010-2014 period, with inventor. Figure 1 breaks the 50 most-cited patents from 2010-2014 into area of focus, revealing, in particular, the rising interest in genotyping and sequencing technologies.

Table 1 Top 20 researchers in 2014

| Inventor/first assignee | Patents granted 2014 | Most-cited patent for 2010-2014 (no. of citations) | H index ${ }^{\text {a }}$ |
| :---: | :---: | :---: | :---: |
| Carlo M. Croce/Ohio State University | 29 | US7670840B2: Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors (34) | 187 |
| George Calin/Ohio State University | 18 | US7670840B2: Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors (34) | 83 |
| Thomas H. Tusch/Rockefeller University; University of Massachusetts; Whitehead Institute; Massachusetts Institute of Technology; Max-Planck-Gesellschaft | 17 | US7772389B2: Anti-microRNA oligonucleotide molecules (3) | 85 |
| Richard D. DiMarchi/Indiana University | 15 | US8454971B2: Glucagon/GLP-1 receptor co-agonists (3) | 44 |
| Peter G. Schultz/Scripps Research Institute | 15 | US7642085B2: Protein arrays (11) | 113 |
| Feng Zhang/Broad Institute | 13 | US8697359B1: CRISPR-Cas systems and methods for altering expression of gene products (14) | 42 |
| Said M. Sebti/University of South Florida | 11 | US8435959B2: Effective treatment of tumors and cancer with triciribine and related compounds (3) | 61 |
| Stefano Volinia/Ohio State University | 11 | US8148069B2: MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers (2) | 74 |
| Stephen R. Quake/University of North Carolina, Chapel Hill | 10 | US7833708B2: Nucleic acid amplification using microfluidic devices (61) | 65 |
| Surinder Pal Singh/CSIRO | 10 | US7807849B2: Synthesis of long-chain polyunsaturated fatty acids by recombinant cells (23) | 26 |
| Jin Q. Cheng/University of South Florida | 10 | US8435959B2: Effective treatment of tumors and cancer with triciribine and related compounds (3) | 60 |
| Phillip D. Zamore/University of Massachusetts; Whitehead Institute; Massachusetts Institute of Technology; Max-Planck-Gesellschaft | 10 | US7691995B2: In vivo production of small interfering RNAS that mediate gene silencing (42) | 68 |
| Bert Vogelstein/Johns Hopkins University | 10 | US7824889B2: Digital amplification (19) | 216 |
| Kenneth W. Kinzler/Johns Hopkins University | 10 | US7824889B2: Digital amplification (19) | 165 |
| Sang Yup Lee/KAIST | 10 | US7670831B2: Conductive carbon nanotubes dotted with metal and method for fabricating a biosensor using the same (8) | 81 |
| David Baltimore/CalTech | 10 | US7737124B2: Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell (6) | 170 |
| James M. Wilson/ University of Pennsylvania | 10 | US7790449B2: Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same and uses (11) | 125 |
| Robert S. Langer/Children's Medical Center Corp.; Harvard | 8 | US7727969B2: Controlled release nanoparticle having bound oligonucleotide for targeted delivery (27) | 213 |
| David L. Kaplan/Tufts University |  | US7842780B2: Silk fibroin materials and use thereof (33) | 93 |
| Karl Deisseroth/Stanford University | 8 | US8398692B2: System for optical stimulation of target cells (12) | 88 |

aH index supplied by researcher, pulled from Google Scholar or calculated through Thomson Reuters Web of Science. CSIRO, Commonwealth Scientific and Industrial Research Organisation, Australia; KAIST, formerly Korea Advanced Institute of Science and Technology, South Korea.

Table 2 Most-cited patents, 2010-2014


Figure 1 Focus area for 50 most-cited patents, 2010-2014.

Inventor/assignee(s)/applicant(s)

| Inventor/assignee(s)/applicant(s) | Publication year | Patent citations, end of 2014 |
| :--- | :---: | :---: |
| Church, George M.; Mitra, Robi D./Harvard University | 2010 | 96 |
| Alexander, Eugene J.; Andriacchi, Thomas P.; Lang, Philipp; <br> Steines, Daniel/Stanford University | 2012 | 95 |
| Esfandyarpour, Hesaam; Ronaghi, Mostafa/Stanford University | 2011 | 86 |
| Miyahara, Yuji; Sakata, Toshiya/National Institute for Materials <br> Science (Japan) | 2011 | 85 |
| Enzelberger, Markus M.; Hansen, Carl L.; Liu, Jian; <br> Quake, Stephen R.; Ma, Chiem/California Institute of Technology | 2010 | 61 |

## First Rounders Podcast:

## Stanley Crooke

Stan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.
http://www.nature.com/nbt/podcast/index.html


[^0]
[^0]:    Brady Huggett is business editor at Nature Biotechnology. Kathryn Paisner is director of research and analytics at IP Checkups, Berkeley, California, USA. e-mail: kpaisner@ipcheckups.com

